Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.23
-0.18 (-1.91%)
At close: Aug 20, 2026, 4:00 PM EDT
9.23
0.00 (0.00%)
After-hours: Aug 20, 2026, 4:04 PM EDT
Xilio Therapeutics Employees
Xilio Therapeutics had 76 employees as of December 31, 2025. The number of employees increased by 12 or 18.75% compared to the previous year.
Employees
76
Change (1Y)
12
Growth (1Y)
18.75%
Revenue / Employee
$843,316
Profits / Employee
-$287,224
Market Cap
60.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | 12 | 18.75% |
| Dec 31, 2024 | 64 | -9 | -12.33% |
| Mar 31, 2024 | 56 | -33 | -37.08% |
| Dec 31, 2023 | 73 | -16 | -17.98% |
| Sep 30, 2023 | 81 | -8 | -8.99% |
| Jun 30, 2023 | 84 | 6 | 7.69% |
| Mar 31, 2023 | 89 | 11 | 14.10% |
| Dec 31, 2022 | 89 | 15 | 20.27% |
| Mar 31, 2022 | 78 | 21 | 36.84% |
| Dec 31, 2021 | 74 | 17 | 29.82% |
| Sep 30, 2021 | 69 | - | - |
| Jun 30, 2021 | 66 | - | - |
| Mar 31, 2021 | 57 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Heron Therapeutics | 128 |
| MindWalk Holdings | 77 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Boundless Bio | 28 |
| INmune Bio | 21 |
| ImageneBio | 18 |
XLO News
- 8 days ago - Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - GlobeNewsWire
- 8 days ago - Xilio Therapeutics Earnings release: Q2 2026 - Filings
- 8 days ago - Xilio Therapeutics Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Xilio Therapeutics appoints Ben Harshbarger as chief legal officer - TheFly
- 7 weeks ago - Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - GlobeNewsWire
- 3 months ago - Xilio Therapeutics Registration statement: Registration filing - Filings
- 3 months ago - Xilio Therapeutics files $250M mixed securities shelf - TheFly